SG Americas Securities LLC Takes Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

SG Americas Securities LLC bought a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 16,081 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock valued at $422,000 after buying an additional 9,500 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Century Therapeutics in the first quarter valued at about $47,000. Vanguard Group Inc. raised its position in Century Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock worth $4,760,000 after purchasing an additional 14,000 shares in the last quarter. Rhumbline Advisers lifted its stake in Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after purchasing an additional 18,828 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after purchasing an additional 44,155 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Trading Down 2.9 %

NASDAQ IPSC opened at $1.36 on Wednesday. The firm has a market cap of $114.92 million, a price-to-earnings ratio of -0.62 and a beta of 1.36. Century Therapeutics, Inc. has a 1-year low of $1.28 and a 1-year high of $5.51. The company has a 50 day moving average of $1.59 and a 200-day moving average of $2.31.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.12. The firm had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.55 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. On average, analysts forecast that Century Therapeutics, Inc. will post -1.8 earnings per share for the current year.

Analyst Ratings Changes

IPSC has been the subject of several analyst reports. HC Wainwright cut their target price on Century Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Rodman & Renshaw began coverage on shares of Century Therapeutics in a research note on Thursday, August 8th. They issued a “buy” rating and a $6.00 target price on the stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.